In Vitro Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program)

Relebactam (formerly MK-7655) is an inhibitor of class A and C β-lactamases, including carbapenemase (KPC), and is currently in clinical development in combination with imipenem-cilastatin. Using Clinical and Laboratory Standards Institute (CLSI)-defined broth microdilution methodology, we evaluated...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrobial agents and chemotherapy 2017-06, Vol.61 (6)
Main Authors: Lob, Sibylle H, Hackel, Meredith A, Kazmierczak, Krystyna M, Young, Katherine, Motyl, Mary R, Karlowsky, James A, Sahm, Daniel F
Format: Article
Language:English
Subjects:
Acinetobacter
Acinetobacter baumannii
Acinetobacter baumannii - drug effects
Anti-Bacterial Agents
Anti-Bacterial Agents - pharmacology
Azabicyclo Compounds
Azabicyclo Compounds - pharmacology
Enterobacter
Enterobacteriaceae
Enterobacteriaceae - drug effects
Gram-Negative Bacteria
Gram-Negative Bacteria - drug effects
Imipenem
Imipenem - pharmacology
Klebsiella pneumoniae
Klebsiella pneumoniae - drug effects
Microbial Sensitivity Tests
Pseudomonas aeruginosa
Pseudomonas aeruginosa - drug effects
Susceptibility
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Relebactam (formerly MK-7655) is an inhibitor of class A and C β-lactamases, including carbapenemase (KPC), and is currently in clinical development in combination with imipenem-cilastatin. Using Clinical and Laboratory Standards Institute (CLSI)-defined broth microdilution methodology, we evaluated the activities of imipenem-relebactam, imipenem, and seven routinely tested parenteral antimicrobial agents against Gram-negative ESKAPE pathogens (including , = 689; , = 72; , = 845; and spp., = 399) submitted by 21 clinical laboratories in the United States in 2015 as part of the SMART (Study for Monitoring Antimicrobial Resistance Trends) global surveillance program. Relebactam was tested at a fixed concentration of 4 μg/ml in combination with doubling dilutions of imipenem. Imipenem-relebactam MICs were interpreted using CLSI imipenem breakpoints. The respective rates of susceptibility to imipenem-relebactam and imipenem were 94.2% (796/845) and 70.3% (594/845) for , 99.0% (682/689) and 96.1% (662/689) for , and 100% (399/399) and 98.0% (391/399) for spp. Relebactam restored imipenem susceptibility to 80.5% (202/251), 74.1% (20/27), and 100% (8/8) of isolates of imipenem-nonsusceptible , , and spp. Relebactam did not increase the number of isolates of spp. susceptible to imipenem, and the rates of resistance to all of the agents tested against this pathogen were >30%. Further development of imipenem-relebactam is warranted given the demonstrated ability of relebactam to restore the activity of imipenem against current clinical isolates of and that are nonsusceptible to carbapenems and its potential as a therapy for treating patients with antimicrobial-resistant Gram-negative infections.
ISSN:0066-4804
1098-6596
DOI:10.1128/AAC.02209-16